Skip to contentC
Cardiff Oncology, Inc.
C
CRDFCardiff Oncology, Inc. Q3 2016 · 10-Q
Revenue$89.00K$89.00K+53.4% vs Q3 2015 Net Income-$10.19M-$10.19MN/M vs Q3 2015 EPS Diluted-$0.34-$0.34N/M vs Q3 2015 Operating Income-$9,924,487N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Cardiff Oncology, Inc. · CIK 1213037 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$7,168,484N/M Margins · derivedOperating margin-11151.1%−100.2 pt vs Q3 2015
Net margin-11450.9%−6733.9 pt vs Q3 2015
ended Sep 30, 2016 · filed Nov 9, 2016 · 40 d after period end